Sell4

Oruka Therapeutics, Inc.

ORKA

Total Value

$6.8M

Net $5.6M sold

Filing Date

Aug 14, 2026

6 transactions

Sales

$5.6M

6 transactions

Trade Summary

On Aug 14, 2026, Quinlan Paul T, General Counsel, sold $6.8M of Oruka Therapeutics, Inc. (ORKA) across 6 transactions. The filing covers Common Stock and reflects net selling of $5.6M. Reported prices ranged from $7.80 to $111.14. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Price at the Time of the Trade

ORKA daily price with the insider's sale marked at $108.49.

Sold near the 6-month high · the stock trades 4% higher today.

Price data is delayed and provided for context only — not investment advice.

Insider Information

Name: Quinlan Paul T
Role: General Counsel
Location: MENLO PARK, CA

Filing Details

Filing Date: Aug 14, 2026
Transaction Date: Aug 14, 2026
Accession Number: 0000907654-26-000077
Form Type: 4
Net Trading Amount: -$5.6M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 14, 2026	Common Stock	10,000	$7.80	Exercise	$78.0K
Aug 14, 2026	Common Stock	42,000	$12.50	Exercise	$525.0K
Aug 14, 2026	Common Stock	3,630	$106.05	Sale	$385.0K
Aug 14, 2026	Common Stock	10,434	$107.14	Sale	$1.1M
Aug 14, 2026	Common Stock	14,696	$107.97	Sale	$1.6M
Aug 14, 2026	Common Stock	10,200	$109.11	Sale	$1.1M
Aug 14, 2026	Common Stock	9,193	$110.00	Sale	$1.0M
Aug 14, 2026	Common Stock	3,847	$111.14	Sale	$427.5K

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 14, 2026	ORKA derivative	10,000	$7.80	Exercise	$78.0K
Aug 14, 2026	ORKA derivative	42,000	$12.50	Exercise	$525.0K

Want live alerts when Quinlan Paul T trades again?

Download Insider Trades to track ORKA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
(F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
(F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive.
(F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive.
(F5)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive.
(F6)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive.
(F7)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive.
(F8)The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
(F9)The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quinlan Paul T

(Last)

(First)

(Middle)

C/O ORUKA THERAPEUTICS, INC.

855 OAK GROVE AVE., SUITE 100

(Street)

MENLO PARK

94025

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Oruka Therapeutics, Inc. [ ORKA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/14/2026		M		10,000	A	$7.8	41,034	D
Common Stock	08/14/2026		M		42,000	A	$12.5	83,034	D
Common Stock	08/14/2026		S⁽¹⁾		3,630	D	$106.0504⁽²⁾	79,404	D
Common Stock	08/14/2026		S⁽¹⁾		10,434	D	$107.1402⁽³⁾	68,970	D
Common Stock	08/14/2026		S⁽¹⁾		14,696	D	$107.9735⁽⁴⁾	54,274	D
Common Stock	08/14/2026		S⁽¹⁾		10,200	D	$109.1131⁽⁵⁾	44,074	D
Common Stock	08/14/2026		S⁽¹⁾		9,193	D	$110.0039⁽⁶⁾	34,881	D
Common Stock	08/14/2026		S⁽¹⁾		3,847	D	$111.1378⁽⁷⁾	31,034	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Warrant (right to buy)	$7.8	08/14/2026		M			10,000	⁽⁸⁾	07/14/2034	Common Stock	10,000	$0	89,996	D
Employee Stock Option (right to buy)	$12.5	08/14/2026		M			42,000	⁽⁹⁾	01/21/2035	Common Stock	42,000	$0	120,500	D

Explanation of Responses:

1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.53 to $106.51, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.54 to $107.53, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.54 to $108.52, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.56 to $109.51, inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.58 to $110.55, inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.66 to $111.22, inclusive.

8. The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.

9. The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

	/s/ Paul Quinlan	08/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0000907654-26-000077.

Oruka Therapeutics, Inc.

Trade Summary

Price at the Time of the Trade

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Quinlan Paul T trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4

Price at the Time of the Trade